Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

about

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

Item

http://www.wikidata.org/entity/Q53832244

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@en

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@nl

type

Item

label

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@en

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@nl

prefLabel

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@en

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@nl

P1476

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

@en

P2093

Janine Marie Traulsen

http://www.w3.org/2001/XMLSchema#string

Tove Holm-Larsen

http://www.w3.org/2001/XMLSchema#string

Trevor Jozef Piatkiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care.

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

OFT, VBP: QED?

P2888

s41669-017-0044-1

P304

109-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S41669-017-0044-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29623619

http://www.w3.org/2001/XMLSchema#string

P932

5972115

http://www.w3.org/2001/XMLSchema#string